Role of Prion Replication in the Strain-dependent Brain Regional Distribution of Prions*
- Ping Ping Hu‡,§,
- Rodrigo Morales‡,
- Claudia Duran-Aniotz‡,¶,
- Ines Moreno-Gonzalez‡,
- Uffaf Khan‡ and
- Claudio Soto‡,¶1
- From the ‡Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Houston Medical School, Houston, Texas 77030,
- §Innovative Drug Research Centre, Chongqing University, Chongqing 401331, China, and
- ¶Universidad de los Andes, Facultad de Medicina, Av. San Carlos de Apoquindo 2200, Las Condes, Santiago, Chile
- ↵1 To whom correspondence should be addressed: University of Texas Medical School, 6431 Fannin St. MSE R422, Houston, Texas 77030. Tel.: 713-500-7086; Fax: 713-500-0773; E-mail: Claudio.Soto{at}uth.tmc.edu.
Abstract
One intriguing feature of prion diseases is their strain variation. Prion strains are differentiated by the clinical consequences they generate in the host, their biochemical properties, and their potential to infect other animal species. The selective targeting of these agents to specific brain structures have been extensively used to characterize prion strains. However, the molecular basis dictating strain-specific neurotropism are still elusive. In this study, isolated brain structures from animals infected with four hamster prion strains (HY, DY, 139H, and SSLOW) were analyzed for their content of protease-resistant PrPSc. Our data show that these strains have different profiles of PrP deposition along the brain. These patterns of accumulation, which were independent of regional PrPC production, were not reproduced by in vitro replication when different brain regions were used as substrate for the misfolding-amplification reaction. On the contrary, our results show that in vitro replication efficiency depended exclusively on the amount of PrPC present in each part of the brain. Our results suggest that the variable regional distribution of PrPSc in distinct strains is not determined by differences on prion formation, but on other factors or cellular pathways. Our findings may contribute to understand the molecular mechanisms of prion pathogenesis and strain diversity.
Footnotes
-
↵* This work was supported in part by National Institutes of Health Grants R01NS049173, P01AI077774, and P01AI106705 (to C. S.). C. S. is the inventor on several patents related to the PMCA technology and is currently Founder, Chief Scientific Officer and Vice-President of Amprion Inc, a biotech company focusing on the commercial utilization of PMCA for prion diagnosis. R. M. is the inventor in some patent applications related to the PMCA technique. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Received July 28, 2015.
- Revision received March 24, 2016.
- © 2016 by The American Society for Biochemistry and Molecular Biology, Inc.











